Literature DB >> 20578127

Comparison of surrogate and direct measurement of insulin resistance in chronic hepatitis C virus infection: impact of obesity and ethnicity.

Khoa D Lam1, Peter Bacchetti, Fahim Abbasi, Claudia E Ayala, Samuel M Loeb, Vidhi Shah, Michael J Wen, Gerald M Reaven, Jacquelyn J Maher, Mandana Khalili.   

Abstract

UNLABELLED: Studies using surrogate estimates show high prevalence of insulin resistance in hepatitis C infection. This study prospectively evaluated the correlation between surrogate and directly measured estimates of insulin resistance and the impact of obesity and ethnicity on this relationship. Eighty-six nondiabetic, noncirrhotic patients with hepatitis C virus (age = 48 +/- 7 years, 74% male, 44% white, 22% African American, 26% Latino, 70% genotype 1) were categorized into normal-weight (body mass index [BMI] < 25, n = 30), overweight (BMI = 25-29.9, n = 38), and obese (BMI > or = 30, n = 18). Insulin-mediated glucose uptake was measured by steady-state plasma glucose (SSPG) concentration during a 240-minute insulin suppression test. Surrogate estimates included: fasting glucose and insulin, glucose/insulin, homeostasis model assessment (HOMA-IR), quantitative insulin sensitivity check index (QUICKI), insulin (I-AUC) and glucose (G-AUC) area under the curve during oral glucose tolerance test, and the Belfiore and Stumvoll indexes. All surrogate estimates correlated with SSPG, but the magnitude of correlation varied (r = 0.30-0.64). The correlation coefficients were highest in the obese. I-AUC had the highest correlation among all ethnic and weight groups (r = 0.57-0.77). HOMA-IR accounted for only 15% of variability in SSPG in the normal weight group. The common HOMA-IR cutoff of < or =3 to define insulin resistance had high misclassification rates especially in the overweight group independent of ethnicity. HOMA-IR > 4 had the lowest misclassification rate (75% sensitivity, 88% specificity). Repeat HOMA-IR measurements had higher within-person variation in the obese (standard deviation = 0.77 higher than normal-weight, 95% confidence interval = 0.25-1.30, P = 0.005).
CONCLUSION: Because of limitations of surrogate estimates, caution should be used in interpreting data evaluating insulin resistance especially in nonobese, nondiabetic patients with HCV.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20578127      PMCID: PMC4391817          DOI: 10.1002/hep.23670

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  40 in total

1.  Oral glucose tolerance test indexes for insulin sensitivity and secretion based on various availabilities of sampling times.

Authors:  M Stumvoll; T Van Haeften; A Fritsche; J Gerich
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

2.  Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease.

Authors:  J Yip; F S Facchini; G M Reaven
Journal:  J Clin Endocrinol Metab       Date:  1998-08       Impact factor: 5.958

3.  Insulin resistance as a predictor of age-related diseases.

Authors:  F S Facchini; N Hua; F Abbasi; G M Reaven
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

4.  Ethnic differences in insulin resistance and its consequences in older Mexican American and non-Hispanic white women.

Authors:  M A Aguirre; C N Jones; D Pei; M L Villa; G M Reaven
Journal:  J Gerontol A Biol Sci Med Sci       Date:  1997-01       Impact factor: 6.053

5.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

Authors:  M Matsuda; R A DeFronzo
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

6.  Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy.

Authors:  R D'Souza; C A Sabin; G R Foster
Journal:  Am J Gastroenterol       Date:  2005-07       Impact factor: 10.864

7.  Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States.

Authors:  S H Mehta; F L Brancati; M S Sulkowski; S A Strathdee; M Szklo; D L Thomas
Journal:  Ann Intern Med       Date:  2000-10-17       Impact factor: 25.391

8.  Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection.

Authors:  Salvatore Petta; Calogero Cammà; Vito Di Marco; Nicola Alessi; Daniela Cabibi; Rosalia Caldarella; Anna Licata; Fatima Massenti; Giuseppe Tarantino; Giulio Marchesini; Antonio Craxì
Journal:  Am J Gastroenterol       Date:  2008-05       Impact factor: 10.864

9.  Roles of insulin resistance and obesity in regulation of plasma insulin concentrations.

Authors:  C N Jones; F Abbasi; M Carantoni; K S Polonsky; G M Reaven
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-03       Impact factor: 4.310

10.  Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites. The Insulin Resistance Atherosclerosis Study.

Authors:  S M Haffner; R D'Agostino; M F Saad; M Rewers; L Mykkänen; J Selby; G Howard; P J Savage; R F Hamman; L E Wagenknecht
Journal:  Diabetes       Date:  1996-06       Impact factor: 9.461

View more
  12 in total

1.  Liver inflammation is a risk factor for prediabetes in at-risk latinos with and without hepatitis C infection.

Authors:  Blaire E Burman; Peter Bacchetti; Claudia E Ayala; Nicholas Gelman; Jennifer Melgar; Mandana Khalili
Journal:  Liver Int       Date:  2014-09-20       Impact factor: 5.828

2.  Effect of male hepatitis B virus infection on outcomes of in vitro fertilization and embryo transfer treatment: insights from couples undergoing oocyte donation.

Authors:  Zhiqin Bu; Huijuan Kong; Jing Li; Fang Wang; Yihong Guo; Yingchun Su; Jun Zhai; Yingpu Sun
Journal:  Int J Clin Exp Med       Date:  2014-07-15

3.  Relationship of hepatitis C virus infection with diabetes in the U.S. population.

Authors:  Constance E Ruhl; Andy Menke; Catherine C Cowie; James E Everhart
Journal:  Hepatology       Date:  2014-08-25       Impact factor: 17.425

4.  Assessment of factors associated with pre-diabetes in HCV infection including direct and dynamic measurements of insulin action.

Authors:  N A Mukhtar; C Ayala; J J Maher; M Khalili
Journal:  J Viral Hepat       Date:  2011-12-18       Impact factor: 3.728

5.  Disentangling the impact of alcohol use and hepatitis C on insulin action in Latino individuals.

Authors:  Rebecca G Kim; Jonathan Kramer-Feldman; Peter Bacchetti; Barbara Grimes; Esteban Burchard; Celeste Eng; Donglei Hu; Marc Hellerstein; Mandana Khalili
Journal:  Alcohol Clin Exp Res       Date:  2021-11-23       Impact factor: 3.455

6.  Fatty Liver Disease in a Prospective North American Cohort of Adults With Human Immunodeficiency Virus and Hepatitis B Virus Coinfection.

Authors:  Mandana Khalili; Wendy C King; David E Kleiner; Mamta K Jain; Raymond T Chung; Mark Sulkowski; Mauricio Lisker-Melman; David K Wong; Marc Ghany; Arun Sanyal; Richard K Sterling
Journal:  Clin Infect Dis       Date:  2021-11-02       Impact factor: 20.999

Review 7.  Hepatitis C and insulin action: An intimate relationship.

Authors:  Hilla Knobler; Stephen Malnick
Journal:  World J Hepatol       Date:  2016-01-18

8.  Depression is not associated with peripheral insulin resistance in patients with chronic hepatitis C infection.

Authors:  S C Shah; J Kornak; M Khalili
Journal:  J Viral Hepat       Date:  2014-09-08       Impact factor: 3.728

9.  Insulin sensitivity and variability in hepatitis C virus infection using direct measurement.

Authors:  Nizar A Mukhtar; Peter Bacchetti; Claudia E Ayala; Jennifer Melgar; Spencer Christensen; Jacquelyn J Maher; Mandana Khalili
Journal:  Dig Dis Sci       Date:  2012-10-21       Impact factor: 3.199

10.  Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin action.

Authors:  Danielle Brandman; Peter Bacchetti; Claudia E Ayala; Jacquelyn J Maher; Mandana Khalili
Journal:  Diabetes Care       Date:  2012-03-07       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.